Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has notably decreased in the past decade. Immunotherapy with immune checkpoint inhibitors have played a noteworthy role in contributing to this improved survival, particularly for patients with non-small cel...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/3/741 |
| _version_ | 1797488726553657344 |
|---|---|
| author | John F. Roller Nirmal K. Veeramachaneni Jun Zhang |
| author_facet | John F. Roller Nirmal K. Veeramachaneni Jun Zhang |
| author_sort | John F. Roller |
| collection | DOAJ |
| description | While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has notably decreased in the past decade. Immunotherapy with immune checkpoint inhibitors have played a noteworthy role in contributing to this improved survival, particularly for patients with non-small cell lung cancer (NSCLC). However, until now the benefits have primarily been seen in patients with advanced or metastatic disease. Several recent early phase and ongoing phase III trials have been assessing whether the treatment benefit of immunotherapy in NSCLC can extend to the neoadjuvant setting for resectable diseases. In this comprehensive narrative review, we evaluate the most recent efficacy and safety data from these studies. We also outline questions that will need to be further examined to legitimate neoadjuvant immunotherapy’s role in NSCLC treatment, including the best surrogate marker of response, the incorporation of liquid biopsy for disease monitoring, the ability to be combined with other treatment modalities, the need for further adjuvant therapy, and potential future treatment combinations. |
| first_indexed | 2024-03-10T00:06:28Z |
| format | Article |
| id | doaj.art-9b92ec23a3724270ab53cfc9992f4039 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:06:28Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9b92ec23a3724270ab53cfc9992f40392023-11-23T16:07:55ZengMDPI AGCancers2072-66942022-01-0114374110.3390/cancers14030741Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLCJohn F. Roller0Nirmal K. Veeramachaneni1Jun Zhang2Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66205, USADepartment of Cardiovascular and Thoracic Surgery, University of Kansas Medical Center, Kansas City, KS 66160, USADivision of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66205, USAWhile lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has notably decreased in the past decade. Immunotherapy with immune checkpoint inhibitors have played a noteworthy role in contributing to this improved survival, particularly for patients with non-small cell lung cancer (NSCLC). However, until now the benefits have primarily been seen in patients with advanced or metastatic disease. Several recent early phase and ongoing phase III trials have been assessing whether the treatment benefit of immunotherapy in NSCLC can extend to the neoadjuvant setting for resectable diseases. In this comprehensive narrative review, we evaluate the most recent efficacy and safety data from these studies. We also outline questions that will need to be further examined to legitimate neoadjuvant immunotherapy’s role in NSCLC treatment, including the best surrogate marker of response, the incorporation of liquid biopsy for disease monitoring, the ability to be combined with other treatment modalities, the need for further adjuvant therapy, and potential future treatment combinations.https://www.mdpi.com/2072-6694/14/3/741neoadjuvantimmunotherapyimmune checkpoint inhibitorsnon-small cell lung cancerresectable lung cancer |
| spellingShingle | John F. Roller Nirmal K. Veeramachaneni Jun Zhang Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC Cancers neoadjuvant immunotherapy immune checkpoint inhibitors non-small cell lung cancer resectable lung cancer |
| title | Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC |
| title_full | Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC |
| title_fullStr | Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC |
| title_full_unstemmed | Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC |
| title_short | Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC |
| title_sort | exploring the evolving scope of neoadjuvant immunotherapy in nsclc |
| topic | neoadjuvant immunotherapy immune checkpoint inhibitors non-small cell lung cancer resectable lung cancer |
| url | https://www.mdpi.com/2072-6694/14/3/741 |
| work_keys_str_mv | AT johnfroller exploringtheevolvingscopeofneoadjuvantimmunotherapyinnsclc AT nirmalkveeramachaneni exploringtheevolvingscopeofneoadjuvantimmunotherapyinnsclc AT junzhang exploringtheevolvingscopeofneoadjuvantimmunotherapyinnsclc |